All articles tagged with #ezh2
A UCSF study identifies four transcription factors (E2F3, EZH2, STAT3, ZFX) that, when modulated, push aging cells toward a younger state; boosting EZH2 in the liver of old mice reduced scarring and improved glucose tolerance, while lab-grown fibroblasts showed rejuvenation-like traits, suggesting a possible universal blueprint for cellular rejuvenation—though long-term safety and broader applicability remain to be confirmed.
Researchers at the NIH have discovered a new role for mutant RAS proteins in cancer progression, revealing that they help release the EZH2 protein from a nuclear complex, leading to the breakdown of the tumor suppressor protein DLC1. This finding suggests that combining RAS inhibitors with drugs that reactivate DLC1 could enhance cancer treatment efficacy, particularly in RAS-driven cancers like pancreatic, colorectal, and lung cancers. The study highlights potential new treatment strategies for these aggressive cancers.